- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07616206
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems (Hybrid CATT1)
Hybrid CATT1: Hybrid Closed Loop Insulin Pumps With Cadisegliatin as Adjunctive Treatment in Patients With Type 1 Diabetes A Phase 2a Double Blind Randomized Cross-Over Study
TTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manage their diabetes. Participants using a hybrid closed loop insulin pump to manage their diabetes will be randomized to either receive blinded cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment or placebo QD along with their insulin treatment. The trial begins with a screening period of up to 2 weeks, followed by a device training and insulin adjustment period of 1-2 weeks leading into the first double-blind treatment period of 6 weeks. There will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participants will cross-over to the treatment that they did not receive in the first treatment period.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
TTP399-206 is a 20 week, Phase 2a trial designed to evaluate efficacy and safety of cadisegliatin in participants with T1D who are using hybrid closed loop (HCL) systems to manage their condition to gather preliminary data to understand how cadisegliatin performs in an HCL setting.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Meaghan Marnell
- Numer telefonu: (336) 888-0435
- E-mail: clinicaltrials@vtvtherapeutics.com
Lokalizacje studiów
-
-
California
-
Modesto, California, Stany Zjednoczone, 95355
- Rekrutacyjny
- Paradigm Clinical Research -Modesto
-
Główny śledczy:
- Gopika Gangupantula, MD
-
San Diego, California, Stany Zjednoczone, 92108
- Rekrutacyjny
- Paradigm Clinical Research Centers, LLC
-
Główny śledczy:
- Schafer Boeder, MD
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- Rekrutacyjny
- Barbara Davis Center for Diabetes
-
Główny śledczy:
- Halis Kaan Akturk, MD
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30318
- Rekrutacyjny
- Atlanta Diabetes Associates
-
Główny śledczy:
- Bruce W Bode, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27514
- Rekrutacyjny
- UNC Eastowne Medical Office Building
-
Główny śledczy:
- Klara Klein, MD, PhD
-
-
Texas
-
Austin, Texas, Stany Zjednoczone, 78731
- Rekrutacyjny
- Texas Diabetes & Endocrinology, P.A.
-
Główny śledczy:
- Thomas Blevins, MD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Key Inclusion Criteria:
- Participants >= 18 years of age
- Fasting C-peptide levels <0.6 ng/ml
- Average TIR < 70% recorded on their personal CGM data collected over the past 7 days prior to Visit 1
- Currently on a hybrid closed loop device for at least 3 months and willing to stay on the same model of pump device for study duration
- Willing to wear a study provided CGM for study duration
- Total bilirubin ≤2×ULN, ALT and AST ≤3×ULN
Key Exclusion Criteria:
- Have Type 2 Diabetes Mellitus (DM), monogenic diabetes, maturity-onset diabetes, other unusual or rare forms of DM, or diabetes resulting from a secondary disease.
- Have been hospitalized for DKA within 3 months
- Have uncontrolled hypothyroidism or hyperthyroidism
- Have QTcF interval > 450 msec for males or > 470 msec for females
- Have a personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias
- Have persistent, uncontrolled hypertension
- Have clinically significant cardiovascular or cerebrovascular disease
- Have proliferative retinopathy or maculopathy requiring acute treatment
- Have a serious concomitant systemic disorder including but not limited to HIV or active Hep B or Hep C
- Have been diagnosed and/or treated for malignancy within 3 years
- Have used any of the following medications within the specified time periods: any non-insulin anti-diabetic therapies (e.g.SGLT-2 inhibitors, GLP-1 receptor agonists, metformin, sulfonylureas, DPP-4 inhibitors, pramlintide, a-glucosidase inhibitors, or glucose dependent insulinotropic polypeptide agonists) within 30 days, antipsychotic medications (e.g. olanzapine, risperidone, clozapine, quetiapine, and haloperidol) within 30 days, systemic corticosteroids for ≥7 days for a temporary medical condition within 30 days,
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Cadisegliatin 800 mg QD, then Placebo
If a participant is randomized to receive cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the placebo QD along with their insulin treatment |
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin
Inne nazwy:
Placebo (insulin alone) |
|
Eksperymentalny: Placebo, then Cadisegliatin 800 mg QD
If a participant is randomized to receive placebo QD along with their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment |
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin
Inne nazwy:
Placebo (insulin alone) |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To assess the change in Time in Range (TIR)
Ramy czasowe: last 2 weeks of the two 6-week treatment periods
|
Time in Range (TIR) based on study CGM in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
last 2 weeks of the two 6-week treatment periods
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
CGM-based metric for glycemic control
Ramy czasowe: last 2 weeks of each treatment period
|
Time In Tight Range (TITR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Ramy czasowe: last 2 weeks of each treatment period
|
Time Above Range (TAR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Ramy czasowe: last 2 weeks of each treatment period
|
Time Below Range (TBR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Ramy czasowe: last 2 weeks of each treatment period
|
Glucose Management Indicator (GMI) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Ramy czasowe: last 2 weeks of each treatment period
|
Glucose variability (GV) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Ramy czasowe: last 2 weeks of each treatment period
|
Time in Range (TIR) > 70% |
last 2 weeks of each treatment period
|
|
Change in glucose control after standardized mixed meal tolerance test (MMTT)
Ramy czasowe: 12 weeks
|
Glucose Peak Plasma Concentration (Cmax) based on study CGM after standardized mixed meal tolerance test (MMTT) |
12 weeks
|
|
Change in glucose control after standardized mixed meal tolerance test (MMTT)
Ramy czasowe: 12 weeks
|
Glucose Area under the plasma concentration versus time curve (AUC) based on study CGM after standardized mixed meal tolerance test (MMTT) |
12 weeks
|
|
To assess the change in Level 1, Level 2 , and Level 3 hypoglycemic incidence
Ramy czasowe: 12 weeks
|
Number of events of Level 1 and Level 2 hypoglycemia as determined by CGM and Level 3 hypoglycemic events in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
12 weeks
|
|
Assess incidence of Serious Adverse Events (SAEs)
Ramy czasowe: 14 weeks
|
Number of Serious Adverse Events (SAEs) |
14 weeks
|
|
Assess incidence of Treatment Emergent Adverse Events (TEAEs)
Ramy czasowe: 14 weeks
|
Number of treatment emergent adverse events (TEAEs) |
14 weeks
|
|
Assess incidence of Treatment Emergent Adverse Events (TEAEs) leading to discontinuation
Ramy czasowe: 14 weeks
|
Number of treatment emergent adverse events (TEAEs) leading to discontinuation of study drug |
14 weeks
|
|
Assess incidence of Adverse Events of Special Interest (AESIs)
Ramy czasowe: 14 weeks
|
Number of adverse events of special interest (AESIs) |
14 weeks
|
|
Change from baseline in average daily total insulin dose
Ramy czasowe: last week of the two 6-week treatment periods
|
Change from baseline in average daily total insulin dose in units (IU) based on manual entry in eDiary records from participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
last week of the two 6-week treatment periods
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Maria Alba, MD, vTv Therapeutics LLC
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- TTP399-206
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .